$QCRH

James Klein Sells 310 Shares of QCR (NASDAQ:QCRH) Stock

James Klein, an insider at QCR Holdings, Inc. (NASDAQ:QCRH), sold 310 shares of the company's stock on April 30th at an average price of $91.00, totaling $28,210. This transaction reduced his ownership by 42.01% to 428 shares. QCR recently reported an EPS of $1.99, beating estimates, but revenue missed expectations, while the company also increased its quarterly dividend to $0.10 per share.

Original reporting
MarketBeat · MarketBeat
Published May 1, 2026, 3:08 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 3:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
James Klein Sells 310 Shares of QCR (NASDAQ:QCRH) Stock — source image
Decision brief

The 30-second read

$QCRHNeutralLow
01

Why it matters

While insider selling might raise short-term caution, the earnings beat and dividend increase could support the stock in the longer term. The mixed signals suggest a cautious approach.

02

Market read

The news has limited impact on the broader market but could influence short-term trading decisions for QCRH.

03

What to watch

Potential upcoming catalysts such as dividend increases or strategic initiatives that could offset concerns from insider selling.

Timing: short-term

Background

James Klein, an insider at QCRH, sold 310 shares at an average price of $91.00, reducing his ownership significantly. The company recently reported earnings beating estimates but missed revenue expectations, and increased its dividend to $0.10 per share.

Company-level read

Ticker impact

$QCRHNeutralMedium confidence
Context

The insider transaction indicates a potential shift in insider sentiment, which could influence market perception.

Expected impact

Potential short-term neutral to slight downward pressure due to insider selling; long-term impact uncertain.

Evidence & confidence

The insider sale might reflect personal portfolio rebalancing rather than company outlook. Earnings beat could support stock price, but revenue miss and insider selling introduce mixed signals.

Market effects

Limited; QCRH operates in the financial sector, which is influenced by broader economic conditions.

Minimal; news pertains to a regional bank with limited influence on regional markets.

Negligible; the event is company-specific and not expected to impact global markets.

Counterpoint

The insider sale could be a personal decision unrelated to company performance, and the earnings beat suggests underlying strength.

Key entities

  • QCR Holdings, Inc.

    A regional bank holding company operating in the financial sector.

Related articles

$QCRHMed

QCR HOLDINGS INC (QCRH): Results of Operations and Financial Condition

QCR HOLDINGS INC (QCRH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qcrh-20260722xex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE FOR IMMEDIATE RELEASE ​ QCR Holdings, Inc. Announces Net Income of $36.3 million for the Second Quarter of 2026 ​ ​ Second Quarter 2026 Highlights ​ ● Net income of $36.3 million, or $2.19 diluted earnings per

$ADBEMed

Adobe’s New CEO Takes Over in December. Is the Open CFO Search the Bigger Risk?

Adobe Inc. (ADBE) named Anil Chakravarthy as its next CEO, effective December 1, 2026. Shantanu Narayen will transition to executive chair. Stifel reiterated a Hold rating with a $200 price target, implying 25% downside. Q2 revenue was $6.62B, up 13% YoY. The CFO role remains interim. Hedge funds slightly reduced positions. Next earnings report is on September 10.

$AAPLLow

John Ternus Just Became Apple's CEO. In 6 Days, He Has to Prove It Matters.

John Ternus became Apple's CEO on September 1, 2026. He will oversee his first product event on September 9, featuring a foldable iPhone, new Apple Watches, and the launch of iOS 27 with Google's Gemini AI. Ternus, a hardware engineer, faces challenges in AI development and investor skepticism about Apple's AI strategy. Apple reported record revenue of $109.4 billion in Q2 2026 but saw a 9.4% stock drop due to weak guidance and AI concerns.

$NVSHighAI 9/10

Novartis, Ionis’ experimental heart drug misses key goal in trial

Novartis and Ionis Pharmaceuticals reported that their experimental heart drug, pelacarsen, failed to reduce the risk of major heart attacks and strokes in a late-stage trial. The drug, targeting genetically inherited cholesterol Lp(a), lowered Lp(a) levels but did not meet its primary endpoint. Novartis shares fell 5%, and Ionis shares dropped 12% in aftermarket trading. The companies plan to present full trial data at an upcoming medical congress.